The Effects of Simvastatin on Proteinuria and Renal Function in Patients with Chronic Kidney Disease

International Journal of Nephrology

Volumn 2015, Issue , 2015, Pages

  Satirapoj, Bancha ^a   Promrattanakun, Anan ^a   Supasyndh, Ouppatham ^a   Choovichian, Panbuppa ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84946029645     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2015/485839     Document Type: Article

References (21)

1. M. T. James, B. R. Hemmelgarn, and M. Tonelli, "Early recognition and prevention of chronic kidney disease," The Lancet, vol. 375, no. 9722, pp. 1296-1309, 2010.
2. B. Satirapoj, O. Supasyndh, N. Mayteedol et al., "Obesity and its relation to chronic kidney disease: a population-based, cross-sectional study of a Thai army population and relatives," Nephrology, vol. 18, no. 3, pp. 229-234, 2013.
3. V. M. Campese, "Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs," Clinical and Experimental Nephrology, vol. 18, no. 2, pp. 291-295, 2014.
4. B. Satirapoj, O. Supasyndh, N. Mayteedol, A. Chaiprasert, and P. Choovichian, "Metabolic syndrome and its relation to chronic kidney disease in a Southeast Asian population," Southeast Asian Journal of Tropical Medicine and Public Health, vol. 42, no. 1, pp. 176-183, 2011.
5. E. S. Schaeffner, T. Kurth, G. C. Curhan et al., "Cholesterol and the risk of renal dysfunction in apparently healthy men," Journal of the American Society of Nephrology, vol. 14, no. 8, pp. 2084-2091, 2003.
6. B. Satirapoj, K. W. Bruhn, C. C. Nast et al., "Oxidized lowdensity lipoprotein antigen transport induces autoimmunity in the renal tubulointerstitium," American Journal of Nephrology, vol. 35, no. 6, pp. 520-530, 2012.
7. T.W. Dasari, D. J. Cohen, N. S. Kleiman et al., "Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the evaluation of drug eluting stents and ischemic events registry)," American Journal of Cardiology, vol. 113, no. 4, pp. 621-625, 2014.
8. S. Sandhu, N. Wiebe, L. F. Fried, and M. Tonelli, "Statins for improving renal outcomes: a meta-analysis," Journal of the American Society of Nephrology, vol. 17, no. 7, pp. 2006-2016, 2006.
9. K. Douglas, P. G. O'Malley, and J. L. Jackson, "Meta-analysis: the effect of statins on albuminuria," Annals of Internal Medicine, vol. 145, no. 2, pp. 117-124, 2006.
10. G. F. M. Strippoli, S. D. Navaneethan, D. W. Johnson et al., "Effects of statins in patients with chronic kidney disease: metaanalysis and meta-regression of randomised controlled trials," British Medical Journal, vol. 336, no. 7645, pp. 645-651, 2008.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease," Kidney International Supplements, vol. 3, pp. 136-150, 2013.
12. P. Cravedi and G. Remuzzi, "Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease," British Journal of Clinical Pharmacology, vol. 76, no. 4, pp. 516-523, 2013.
13. W. F. Keane, "The role of lipids in renal disease: future challenges," Kidney International, Supplement, vol. 57, no. 75, pp. S27-S31, 2000.
14. C. K. Abrass, "Cellular lipidmetabolismand the role of lipids in progressive renal disease," American Journal of Nephrology, vol. 24, no. 1, pp. 46-53, 2004.
15. H. Oda and W. F. Keane, "Recent advances in statins and the kidney," Kidney International Supplements, vol. 56, no. 71, pp. S2-S5, 1999.
16. V. M. Campese, M. K. Nadim, and M. Epstein, "Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?" Journal of the American Society of Nephrology, vol. 16, no. 3, supplement 1, pp. S11-S17, 2005.
17. S. Bianchi, R. Bigazzi, A. Caiazza, and V. M. Campese, "A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease," American Journal of Kidney Diseases, vol. 41, no. 3, pp. 565-570, 2003.
18. V. G. Athyros, D. P. Mikhailidis, A. A. Papageorgiou et al., "The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study," Journal of Clinical Pathology, vol. 57, no. 7, pp. 728-734, 2004.
19. M. Tonelli, L. Moyé, F. M. Sacks, T. Cole, and G. C. Curhan, "Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease," Journal of the American Society of Nephrology, vol. 14, no. 6, pp. 1605-1613, 2003.
20. Heart Protection Study Collaborative Group, "MRC/BHFHeart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial," The Lancet, vol. 361, no. 9374, pp. 2005-2016, 2003.
21. J. Shepherd, J. J. P. Kastelein, V. Bittner et al., "Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study," Clinical Journal of the American Society of Nephrology, vol. 2, no. 6, pp. 1131-1139, 2007.